Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Kunihiko Tokashiki"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 180-185 (2024)
Introduction: Head and neck photoimmunotherapy (HN-PIT) uses a combination of drugs and laser illumination to specifically destroy tumor cells. Lemierre’s syndrome is an infectious disease with severe systemic symptoms caused by prior infection in
Externí odkaz:
https://doaj.org/article/0ef4d409bef64b77b2dbea37311dfcec
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 169-174 (2024)
Introduction: Head and neck photoimmunotherapy (HN-PIT) has been conditionally approved by the Japanese government for the treatment of unresectable locally advanced or locally recurrent head and neck cancer since January 2021. HN-PIT makes local tre
Externí odkaz:
https://doaj.org/article/71e0d00c0eb64131919f3ebe9d859e20
A Case of Oropharyngeal Carcinoma with an Oblique Neck that Benefited from Transoral Robotic Surgery
Autor:
Tatsuya Yamakura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Kunihiko Tokashiki, Takuma Kishida, Tatsuya Ito, Kiyoaki Tsukahara
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 930-934 (2023)
Transoral robotic surgery (TORS) and transoral videolaryngoscopic surgery (TOVS) are minimally invasive procedures for early-stage head and neck cancers. However, due to its unique nature, transoral resection often leads to skeletal and anatomical di
Externí odkaz:
https://doaj.org/article/05578e7a8dce4eabb580a71d01e00d37
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 1, Pp 34-39 (2022)
Photoimmunotherapy (PIT) targets and destroys tumor cells through irradiation with 690-nm red light after the administration of cetuximab sarotalocan sodium, which contains IRDye700DX bound to cetuximab. In Japan, PIT is a new treatment that is cover
Externí odkaz:
https://doaj.org/article/1c4a49e5f7c6490a995a798bd6e8a049
Publikováno v:
Case Reports in Otolaryngology, Vol 2013 (2013)
Primary submandibular gland oncocytic carcinoma is a rare pathology, with only 10 cases being reported to date. We encountered a case of primary submandibular gland oncocytic carcinoma and report it herein. The patient was a 69-year-old man who came
Externí odkaz:
https://doaj.org/article/1aeec7bbadf841808556cec0ff66f1f2
Autor:
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer Research. 43:2717-2724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51a71d153e2a5a6bd0991ba6fe9d92b
https://doi.org/10.21873/anticanres.16438
https://doi.org/10.21873/anticanres.16438
Publikováno v:
Cancer Diagnosis & Prognosis; Jan/Feb2024, Vol. 4 Issue 1, p85-90, 6p
Autor:
Hiroki Sato, Takuma Kishida, Isaku Okamoto, Akira Shimizu, Takuro Okada, Kiyoaki Tsukahara, Kunihiko Tokashiki
Publikováno v:
Auris Nasus Larynx. 49:727-732
A 30-year-old man presented with swelling in the lower left ear. Close examination led to a diagnosis of parotid gland cancer, T4N0M0 Stage IVA, so total resection of the left parotid gland and left neck dissection were performed. Pathological examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6982cc5c2a6d668f528f41323fedcac5
https://doi.org/10.1016/j.anl.2021.02.016
https://doi.org/10.1016/j.anl.2021.02.016
Publikováno v:
In Vivo; Nov/Dec2023, Vol. 37 Issue 6, p2845-2848, 4p
Autor:
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer Research. 42:1607-1613
There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be423a1d812728e74383ab8b5337273d
https://doi.org/10.21873/anticanres.15635
https://doi.org/10.21873/anticanres.15635